BiotechTube

Pimasertib + Dacarbazine

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

Conditions

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

Trial Timeline

Dec 5, 2012 → Oct 24, 2016

NCT ID
NCT01693068

About Pimasertib + Dacarbazine

Pimasertib + Dacarbazine is a phase 2 stage product being developed by Merck for N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01693068. Target conditions include N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma.

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01693068Phase 2Completed